GSK, Sanofi launch late-stage COVID-19 vaccine study

GlaxoSmithKline (GSK) and Sanofi have begun enrolling participants into a Phase III clinical study of their adjuvanted recombinant-protein COVID-19 vaccine candidate. The study, which will include more than 35,000 volunteers aged 18 years and older, will aim to evaluate if the vaccine can prevent symptomatic COVID-19 vaccine in participants who have not previously been infected with SARS-CoV-2.